ABBV.NYSEAbbvie INC

Form 4: AbbVie Executive Timothy J. Richmond Reports Stock Option Exercise and Share Sales

Sentiment:

SEC Form 4


EVP and Chief HR Officer of AbbVie, Timothy J. Richmond, reports exercising stock options and selling shares of common stock on March 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

  • On March 1, 2024, Timothy J. Richmond, EVP and Chief HR Officer of AbbVie, exercised stock options to acquire 45,700 shares of AbbVie common stock at a price of $61.36 per share.
  • Richmond then sold a total of 75,680 shares of AbbVie common stock in multiple transactions at weighted average prices ranging from $176.35 to $177.71.
  • These sales were executed under a pre-arranged Rule 10b5-1 trading plan established on November 13, 2023.
  • Following these transactions, Richmond directly owns 13,837 shares of AbbVie common stock.
  • Richmond also continues to hold options to purchase 0 shares of AbbVie common stock at an exercise price of $61.36.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The filing simply reports transactions by an executive under a pre-existing plan. There's no inherent positive or negative signal.

Positives

  • The executive's transactions are being conducted under a pre-arranged Rule 10b5-1 trading plan, which can mitigate concerns about insider trading.

Risks

  • Executive stock sales, even under a 10b5-1 plan, can sometimes be perceived negatively by investors if they are interpreted as a lack of confidence in the company's future prospects.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies, and are closely monitored by investors for signals about a company's prospects. Rule 10b5-1 plans are frequently used to allow insiders to sell shares without raising concerns about insider trading.

Comparison to Industry Standards

  • Executive compensation practices, including stock options and sales, are generally benchmarked against peer companies in the pharmaceutical industry.
  • Companies like Johnson & Johnson (JNJ), Pfizer (PFE), and Merck (MRK) serve as comparables for executive compensation and stock ownership analysis.
  • The use of Rule 10b5-1 plans is a standard practice among executives at publicly traded companies to manage their stock sales in a transparent and compliant manner.

Stakeholder Impact

  • The transactions may have a minor impact on shareholders, depending on how they interpret the executive's stock sales.
  • The impact on employees, customers, suppliers, and creditors is likely to be negligible.

Key Dates

DateDescription
2018-02-16Option exercisable date
2023-11-13Date of Rule 10b5-1 plan establishment
2024-02-15Option expiration date
2024-03-01Date of stock option exercise and share sales
2024-03-05Date of signature

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.